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1. INTRODUCTION 
 The goal of any drug delivery system is to provide a therapeutic amount of 
drug to the proper site in the body, to achieve promptly and then maintain the desired 
drug concentration. 
 
 Conventional drug delivery system achieves as well as maintains the drug 
concentration with in the therapeutically effective range needed for treatment only 
when taken several times a day. This results in a significant fluctuation in drug level 
(Chien YM., 1992). 
 
 The concept of designing specified delivery system to achieve selective drug 
targeting has been originated from the perception of Paul Ehrlich, who proposed drug 
delivery to be as a “magic bullet”. 
 
 Controlled & Novel delivery envisages optimized drug in the sense that the 
therapeutic efficacy of a drug is optimized, which also implies nil or minimum side 
effects. It is expected that the 21
st
 century would witness great changes in the area of 
drug delivery. The products may be more potent as well as safer. Target specific 
dosage delivery is likely to overcome much of the criticism of conventional dosage 
forms. The cumulative outcome could be summarized as optimized drug delivery that 
encompasses greater potency & greater effectiveness, lesser side effects and toxicity, 
better stability, low cost hence greater accessibility, ease of administration and best 
patient compliance (Jain N K., 2001). 
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1.1 RATIONALE OF DRUG TARGETING (Jain N K., 2001) 
 The site-specific targeted drug delivery negotiates an exclusive delivery to 
specific pre identified compartments with maximum activity of drugs and 
concomitantly reduced access of drug to irrelevant non-target cells. The controlled 
rate & mode of drug delivery to pharmacological receptor and specific binding with 
target cells as well as bioenvironmental protection of the drug in route to the site of 
action are specific features of targeting. Invariably, every event stated contributes to 
higher drug concentration at the site of action and resultant lowers concentration at 
non-target tissue where toxicity might crop up. The high drug concentration at the 
target site is relative cellular result of the uptake of the drug vehicle, liberation and 
efflux of free drug from the target site. 
 
 Targeting is signified if the target compartment is distinguished from the other 
compartments, where toxicity may occur and also if the active drug could be placed 
predominantly in the proximity of target site. The restricted distribution of the parent 
drug to the non-target site(s) with effective accessibility to the target site(s) could 
maximize the benefits of targeted drug delivery. 
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Figure No: 1 Principle & Rationale of drug targeting: 
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1.2 APPROACHES (Vyas S P., 2001) 
 The various approaches of vectoring the drug to the target site can be broadly 
classified as: 
 Passive targeting 
 Inverse targeting 
 Active targeting 
 Dual targeting  
 Double targeting 
 Combination targeting 
 
 PASSIVE TARGETING 
 System that target the systemic circulation are generally characterized as 
passive” delivery systems (i.e., targeting occurs because of the body’s natural 
response to the physicochemical characteristics of the drug or drug-carrier system. It 
is a sort of passive process that utilizes the natural course of biodistribution of the 
carrier system through which, it eventually accumulation in the organ compartment(s) 
of the body. The ability of some colloids to be taken up by the RES especially in liver 
and spleen has made them as ideal vectors for passive hepatic targeting of drugs to 
these compartments. 
  
 This category of targetable devices includes drug bearing bi-layer vesicular 
systems as well as cellular of micron or sub micron size range. 
 
 INVERSE TARGETING 
 It is essentially based on successful attempts to circumvent and avoid passive 
uptake of colloidal carriers by reticulo endothelial system (RES). This effectively 
leads to the reversion of biodistribution trend of the carrier and hence the process is 
referred to as inverse targeting. One strategy applied to achieve inverse targeting is to 
suppress the function of RES by pre-injection of a large amount of blank colloidal 
carriers or macromolecules like dextran sulphate. This approach leads to RES 
blockade and as a consequence impairment of host defense system. Alternate 
strategies include modification of the size, surface charge, composition, surface 
rigidity and hydrophilicity of carriers for desirable biofate. 
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 ACTIVE TARGETING 
 Conceptually, active targeting exploits modification or manipulation of drug 
carriers to redefine its biofate. The natural distribution pattern of the drug carrier 
composites is enhanced using chemical, biological and physical means, so that it 
approaches and is identified by particular biosites. The facilitation of the drug-carrier 
to target cells through the use of ligands or engineered homing devices to increase 
receptor mediated (or I some cases receptor independent but epitopes based) 
localization of the drug and target specific delivery of drug(s) is referred to as active 
targeting. 
 
 This target approach can further be classified into three different levels of 
targeting 
  
First order targeting 
 It refers to restricted distribution of the drug-carrier system to the capillary bed 
of a predetermined target site, organ or tissue.  Compartmental targeting in lymphatic, 
peritoneal cavity, cerebral ventricles, lungs, joints, eyes, etc., represents first order 
targeting (it could also be categorized as level of passive targeting). 
 
Second order targeting 
 The selective delivery of drugs to a specific cell type such as tumor cells and 
not to the normal cells is referred as second order drug targeting. The selective drug 
delivery to the kupffer cells in the liver exemplifiers this approach. 
 
Third order targeting 
 The third order targeting is defined as drug delivery specifically to the 
intracellular site of target cells. An example of third order targeting is the receptor 
based ligand-mediated entry of a drug complex into a cell by endocytosis, lysosomal 
degradation of carrier followed by release of drug intracellularly or gene delivery to 
nucleolus. 
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Ligand mediated targeting 
 Targeting components, which have been studied and exploited are pilot 
molecules themselves (bioconjugates) or anchored as ligands on some delivery 
vehicle (drug-carrier system). All the carrier systems, explored So far, in general, are 
colloidal in nature. They can be specifically functionalized using various biologically 
relevant molecular ligands including antibodies, polypeptides, oligosaccharides 
(carbohydrates), viral proteins and fusogenic residues. The ligands afford specific 
avidity to drug carrier. The engineered carrier constructs selectivity deliver the drug to 
the cell or group of cells generally referred to as target. The cascade of events 
involved in ligand negotiated specific drug delivery is termed as ligand driven 
receptor mediated targeting. 
 
Physical targeting (triggered Release) 
 The selective drug delivery programmed and monitored at the external level 
(ex vivo) with the help of physical means is referred to as physical targeting. In this 
mode of targeting, some characteristics of the bioenvironmental are used either to 
direct the carrier to a particular location or to cause selective release of its content. 
 
 DUAL TARGETTING 
 This classical approach of drug targeting employs carrier molecules, which 
have their own intrinsic antiviral effect thus synerging the antiviral effect of the 
loaded active drug. Based on this approach, drug conjugates can be prepared with 
the fortified activity profile against the viral replication. A major advantage is that 
the virus replication process can be attacked at multiple points, excluding the 
possibilities of resistant viral strain development. 
 
 DOUBLE TARGETING 
For a new future trend, drug targeting may be combined with another 
methodology, other than passive and active targeting for drug delivery systems. 
The combination is made between spatial control and temporal control of drug 
delivery. 
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The temporal control of drug delivery has been developed in terms of 
control drug release prior to the development of drug targeting. If spatial 
targeting is combined with temporal control results in an improved therapeutic 
index by the following two effects. First, if drug release or activation is occurred 
locally at therapeutic sited, selectively is increased by multiplication of the spatial 
selectively with the local release/activation. Second, the improvement in the 
therapeutic index by a combination of a spatially selective delivery and a 
preferable release pattern for a drug, such as zero order release for a longer time 
period of the drugs. When these two methodologies are combined, it may be 
called “Double targeting”. 
 COMBINATION TARGETING 
Petit and Gombtz., 1998 have suggested the term combination targeting 
for the site specific delivery of proteins and peptides. These targeting systems are 
equipped with carriers. Polymers and homing devices of molecular specificity 
that could provide a direct approach to target site. Modification of proteins and 
peptides with natural polymers, such as polysaccharides, or synthetic polymers, 
such as poly (ethylene glycol), may alter their physical characteristics and favor 
targeting the specific compartments, organs or their tissues within the 
vasculature. 
1.2.3 LIMITATIONS OF TARGETED DRUG DELIVERY 
SYSTEMS (Cheiny M., 1992) 
 
Several problems have been identified which require alterations in targeting 
strategies particularly, in vivo. These include: 
 
 Rapid clearance of targeting systems especially antibody targeting carriers 
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 Immune reactions against intravenous administered carrier systems. 
 Target tissue heterogenecity. 
 Problems of insufficient localizations of targeted systems into tumor cells. 
 Down regulation and sloughing of surface epitopes. 
 Diffusion and redistribution of released drug leading to no-specific 
accumulation. 
 
1.2.4 CARRIERS USED IN TARGETING DRUG DELIVERY 
SYSTEMS 
 
Carrier is one of the most important entities essentially required for succ essful 
transportation of the loaded drug(s). They are drug vectors, which sequester, transport 
and retain drug en route. While eluting or delivering it within or in vicinity of target. 
 
Colloidal carriers: 
 Vesicular systems: Liposomes; pharmacosomes; virosomes; 
immunoliposomes. 
 Micro particulate systems: Nanoparticles; Microparticles; Magnetic 
Microspheres; Nanocapsules.  
 Cellular carriers: Resealed erythrocytes; Serum albumin; Antibodies; 
Platelets; Leukocytes.  
 
Supramolecular delivery system: 
 
 Micelles; reverse micelles; mixed micelles; polymeric micelles; liquid 
crystal: lipoproteins. 
 
Polymer based systems: 
 
 Signal sensitive; muco-adhesive; biodegradable; bioerodable; solute 
synthetic polymeric carriers. 
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Macromolecular carriers: 
Proteins, glycoproteins, neo glycoproteins and artificial viral envelops 
(AVE); Glycosylated water-soluble polymers (poly-L-lysine). 
Mabs; Immunological Fab fragments; antibody enzyme complex & 
bispesific Abs; Toxins, immunotoxin & rCD4 toxin conjugates 
Lecithins (Con A) & polysaccharides. 
 
1.3 INTRODUCTION TO LIPOSOMES 
 Liposomes (marc J. Ostro., 1987) have reached the clinical only recently, but 
they are not a new invention Alec D. Bangham of the Agricultural Research Council’s 
institute of Animal physiology in Cambridge, England, inadvertently produced the 
first liposome in 1961, while evaluating the effect of phospholipids on blood clotting. 
When Bangham put water in a flask containing a phospholipid film, the water 
molecules to arrange themselves in to what he discovered. He found vesicles 
composed of a bilayered phospholipids membrane surrounding water entrapped from 
the environment.              
Phospholipids form closed, fluid-filled spheres when they are mixed with 
water in part because the molecules are amphipathic; they have a hydrophobic “tail” 
and a hydrophilic or polar “head”. Two fatty acid chains, each composed of 10 to 24 
carbon atoms, make up the hydrophobic tail of most naturally occurring phospholipids 
molecules. Phosphoric acid bound to any of several water soluble molecules 
composes the hydrophilic head. When a high enough concentration of phospholipids 
is mixed with water, the hydrophobic tails spontaneously herd together to exclude 
water, whereas the hydrophilic heads bind to water. 
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The result is a bilayer in which the fatty acid tails in to the membrane’s 
interior and the polar head groups point outward the polar groups at one surface of the 
membrane point toward the liposome’s interior and those at the other surface point 
toward the external environment. It is this remarkable reactivity of phospholipids to 
water that enables workers to load medications in to liposomes. In a liposome form, 
any water soluble molecules that have been added to the water are incorporated in to 
the aqueous spaces in the interior of the spheres, whereas any lipid soluble molecules 
added to the solvent during vesicle formation are incorporated in to the lipid layer. 
 
Liposomes employed for drug delivery typically range in diameter from 250 
angstrom units to several micrometers and are usually suspended in a solution. They 
have two standard forms: “onion-skinned” multilamellar vesicles (MLVs) made up of 
several lipid bilayers separated by fluid, and unilamellar vesicles, containing of a 
single bilayer surrounding an entirely fluid core. The unilamellar vesicles are typically 
characterized as being small (SUVs) or large (LUVs). 
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                       Liposome structure formed by phospholipids 
                             Figure No. 2 Structure of liposome    
 
 
 
                            
 
                             Shape of phospholipids molecule 
                           Figure No. 3 Shape of phospholipids molecule. 
 
 
 
Hydrophilic drug 
loaded in liposome. 
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1.4 STRUCTURAL COMPONENTS OF LIPOSOMES: 
 
The main components of liposome are 
 
 Phospholipids 
o Phosphoglycerides 
o Sphingolipids 
 Cholesterol 
 
1.5 TYPES OF LIPOSOMES (Marc J Ostro., (1987) & Amarnath            
Sharma (1997) 
 
1.5.1 Classification based on structural parameters 
 
1. Multilamellar Large vesicles (MLV 0.1-6µm) 
2. Small unilamellar vesicles (SUV 0.02-0.05 µm) 
3. Large unilamellar vesicles (LUV>0.06) 
4. Oligolamellar vesicles (OLV 0.1-1 µm ) 
5. Unilamellar vesicles (UV- wide range) 
6. Gaint unilamellar vesicles (GUV –cell size vesicle s>1 µm) 
7. Medium Unilamellar vesicles 
8. Multivesicular vesicle (>1 µm) 
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      Figure No: 4 Schematic illustrations of liposomes of different size and 
number of  Lamellae. SUV: Small unilamellar vesicles; LUV: Large unilamellar 
vesicles; MLV: Multilamellar vesicles; MVV: Multivesicular vesicles. 
 
1.5.2 Classification 
 
The Liposomes are classified as vesicular systems from biological origin and non 
biological origin. Specialized for cellular drug targeting are grouped separately (Vyas 
and Dexit, 1998). 
 
Biological origin 
 
1) Liposomes 
 
Vesicles can be formed from adverse range of amphiphillic building blocks, 
which are prepared mainly with lecithin (Bangham et al., 1965: grogoriadis, 1972) 
and synthetic phospholipids. 
                                                                                                     
Introduction 
 
Dept., of Pharmaceutics, The Erode College of Pharmacy & Research Institute, Erode. Page 14 
 
 
2) Polymerizable Liposomes (Fendler, 1982) 
 
This type of Liposomes mainly contains phospholipid derivatives of 
polymerizable group in their fatty acyl chains. The diacetylenic lipids, methacryloyl 
lipids, dienoyl lipids are used as building blocks for this type. 
 
3) Polymer capped Liposomes (Regen et al., 1984) 
 
Here the cationic phospholipids are ion-paired with a polymerizable anion like 
methacrulate ion. The elute is dispersed in Liposomes followed by polymerization 
using irradiation or chain initiator. In this the polymeric network encases the bilayer 
of Liposomes without covalent linkage. 
 
4) Polymerized phospholipid Liposomes (Weber et al., 1987) 
 
Phospholipid polymerized with 1, 2-bis-(2-mercaptohexadecanoyl) 3-glycerol-
3-phosphocholine could readily assemble to form this type of vesicles. 
 
5) Redox Liposomes (Samvel et al., 1985) 
 
             This type of vesicles based on thiol-disulfide redox cycle. 
 
6) Polymer grafted Liposomes (Allen et al., 1991) 
 
These types of Liposomes are formed by natural or synthetic phospholipids 
with covalently linked PEG polymer. 
 
7) Virosomes (Al-Ahdal et al., 1994) 
 
Virosomes, like Liposomes are spiked with virus glycoprotein like Sendai 
virus. They mainly contain reconstituted viral spiked glycoprotein. 
 
                                                                                                     
Introduction 
 
Dept., of Pharmaceutics, The Erode College of Pharmacy & Research Institute, Erode. Page 15 
 
8) Emulsomes (Amselem et al., 1994) 
 
Emulsomes were constructed by phospholipids which have high concentration 
along with high molecular weight fatty acids. 
 
Non-biological origin 
 
1) Niosomes (Handijani-vila et al., 1979) 
 
The single chain non-ionic surfactants of low HLB values were contributed 
mainly in construction of Liposomes. 
 
2) Discomes (Vyas et al., 1997) 
 
Solubilization of niosomes with non-ionic surfactant (Polyoxy ethylene acetyl 
ether class) forms discomes. 
 
3) Pharmacosomes (Vizaglou et al., 1986) 
 
The Pharmacosomes are formed by mesogenic drug which itself acts as a 
building block in combination with a lipid. 
 
4) Ufasomes (Gebicks et al., 1973) 
 
The single chain unsaturated fatty acids (Oleic, linoleic acid) are the main 
building blocks in this type. 
 
5) Cryptosomes (Blume et al., 1990) 
 
Combination of natural phospholipids with suitable poly-oxythylene 
derivatives of PE (Phosphatidylethanolamine) gives Cryptosomes. 
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Specialized Liposomes 
 
1) Glycoprotein bearing Liposomes 
Incorporation of glycoprotein in bilayer membrane gives this type of vesicles. 
The major glycoprotein, the glycoprotein of the human erythrocyte plasma membrane 
has been incorporated in to Liposomes. 
 
2) Glycolipid bearing Liposomes 
 
Glycolipid (like monosialo-gangliaside) appended liposome are prepared and 
tried to target lymphocytes. 
 
3) Glycoside bearing Liposomes 
 
The plant glycosides, asiaticiside and corhorusin D containing rhamnose and 
glucose in terminal sugar respectively have been grafted on the liposomal that are 
tried against M.leprae and M.tuberculosis by Medda et al., (1995) 
 
4) Protein coated Liposomes (Longaman and co-workers, 1995) 
 
Liposomes with protein immobilized on the surface are investigated to target 
extra vascular spaces by using biotinylated antibody and streptavidin. 
 
5) Peptide carrying Liposomes (Zalipsky et al., 1995) 
 
In this type the peptide conjugated with PWG (DSPE) which was incorporated 
in liposome for systemic drug delivery. 
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6) Polysaccharide bearing Liposomes 
 
Polysaccharide coated Liposomes used for targeting to Legionella 
pneumophilia infected human monocyte and guinea pig.   
 
7) Bacteriosomes, Proteoliposomes 
 
Lectinization of Liposomes was used for targeting to Hela cells and 
streptococcus etc., 
 
8) Bioreactive Liposomes (Gregoriadis et al., 1983) 
 
Enzymes were encapsulated in Liposomes and were called as Bioreactive 
Liposomes. Eg. Streptokinase containing Liposome. 
 
9) Immunosomes 
 
Immunosomes are liposomal constructs engineered by employing 
immunoglobulins as pilot molecules anchored on or as a structural part of vesicles to 
confer specificity to a wide range of target sites. These are classified in to 
 
a) Immunoliposomes 
 
b)  Haptenated Liposomes 
       
c) Immunotoxin anchored Liposomes 
 
d) Immunoprotective Liposomes 
 
e) Immunoadjuvant Liposomes 
 
10) Transferin based Liposomes (Wagner et al., 1994) 
 
Transferin is an important glycoprotein which is used for coating Liposomes 
and selectively targeted to proliferating neoplastic cell lines. 
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11) Enzymosomes 
 
In this type enzymes are covalently immobilized or coupled to the surface of 
liposome and if a prodrug is administered simultaneously, it can convert to active 
form at target site by immobilized enzyme. 
 
1.6 Liposomes delivered intercellularly 
 
Liposomes deliver their contents to the cytoplasm of cells in culture either by 
fusion with the outer cell membrane or by endocytosis where upon they are 
concentrated in acidic lysozymal sacs. (Ostro et al., 1987) 
 
1) Inter membrane transfer 
 
Inter membrane transfer of lipid component can take place upon close 
approach of the two phospholipid bilayers without the need for disruption of the 
liposome. Only specific phospholipids exchange (PC &PE) via intermediate of a 
specific cell surface exchange protein. Similarly Liposomes and lipoproteins (HDL) 
interactions is important liposomal stability in circulation. Addition of cholesterol 
retards immediate destabilization of Liposomes. 
 
2) Contact release 
 
The liposome content with cell causes an increase in permeability on the 
entrapped content through bilayer membrane, curiously, cell induced leakage of 
solutes have been observed to be greater in membranes with cholesterol concentration 
above 30%. This process strengthened by means of receptor/ligand between the two 
membranes. 
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3) Adsorption 
 
The adsorption of Liposomes takes place either as a result of physical 
attractive forces, or as a result of binding by specific receptors to ligands on the 
vesicle membranes. The attraction depends on the specific cell surface protein. This 
interaction was more in case of gel phase of liposome. 
 
4) Fusion 
 
Close approaching of Liposomes and cell membranes can lead to fusion of the 
two resulting in complete mixing of liposomal lipids with those of the plasma 
membrane of the cell and the liposomal content released in to cytoplasm. This process 
takes place after phagocytosis and endocytosis of Liposomes. Inside the Endosome, 
Liposome were affected by acidic pH. There by this will completely fuse and deliver 
the drug content in to cytoplasm. 
 
1.7 Methods of liposome preparation 
 
1. Passive loading techniques 
 
a. Mechanical dispersion methods 
 Lipid film hydration by hand shaking non-hand shaking or 
freeze drying. 
 Micro emulsification 
 Sonication 
 French pressure cell 
 Membrane extrusion 
 Dried reconstituted vesicles 
 Freeze thawed Liposomes 
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b. Solvent dispersion methods 
 Ethanol injection 
 Ether injection 
 Double emulsion vesicles 
 Reverse phase evaporation vesicles 
 Stable plurilamellar vesicles 
 
c. Detergent removal methods 
 Detergent removal from mixed micelles  
 Dialysis 
 Column chromatography 
 Dilution 
 Reconstituted sandal virus enveloped vesicles 
 
2. Active loading techniques 
 
ADVANTAGES OF LIPOSOMES 
 
The pharmaceutical and pharmacological justification of the use of liposomes 
as drug carriers is as follows: 
 
1. Liposomal supply both a lipophilic environment and aqueous “milleu 
interne” in one system and are therefore suitable for the delivery of 
hydrophobic, amphipatic and hydrophilic drugs and agents. 
2. Liposomes are chemically and physically well characterized entities. 
3. The biological fate of liposomes after their administration is related to 
their composition and physical properties. 
4. Liosomes are biocompatible due to their biodegradability, low toxicity 
and lack of immunogenicity. 
5. Liposomes can serve as device for controlled release of drugs in body 
fluids (micro reservoir concept) and inside cells (after endocytic 
uptake). 
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6. Liposomes help to reduce exposure of sensitive tissues to toxic drugs. 
7. Liposomes can be administered through mostnroutes of administration 
including ocular, pulmonary, nasal, oral, intramuscular, subcutaneous, 
topical and intravenous. 
8. Pharmacokinetics and in-vivo distribution of liposomes can be 
controlled by their port of entry combined with their lipid composition 
and size. 
DISADVANTAGES OF LIPOSOMES 
 
1. Aggregation, fusion and drug leakage during storage. 
2. Chemically instable i.e., degradable by oxidation and hydrolysis. 
3. In physiological environment they are destabilized by high density 
lipoproteins(HDL) 
4. Purity of natural phospholipids and cost of production. 
5. They undergo complete mediated phagocytosis and lipid exchange 
reactions. 
 
1.8 FACTORS EFFECTING DRUG ENTRAPMENT AND RELEASE 
CHARACTERISTICS 
 
Factors effecting drug entrapment and release characteristics of Liposomes 
include, 
 
1. Charge 
2. Lipid content 
3. partition coefficient 
4. Method of preparation of Liposomes 
 
Charge 
 
The presence of negatively charged lipid such as Phosphotidyl serine, 
Phosphatidicacid, Phosphotidyl inositol and Phosphotidyl glycerol or positively 
charged detergents such as stearylamine will tend to increase the intercellular distance 
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between successive bilayers in the MLV structure and thus lead to greater overall 
entrapped volume. 
 
Lipid content 
 
The total amount of liposomal lipid used and thee internal volume of the 
Liposomes will affect the total amount of loading of non-polar and polar group in to 
Liposomes. Efficient capture will depend on the use of drugs at concentration which 
do not exceed the saturation limit of the drug in the aqueous compartment or the lipid 
bilayers. 
 
Partition coefficient 
 
The location of drug within a liposome is based on the partition coefficient of 
the drug between aqueous compartments and lipid bilayer and the maximum amount 
of drug that can be entrapped within Liposomes in dependent on its total solubility in 
each phase. 
 
Method of preparation of Liposomes 
 
The method of preparation of Liposomes can also affect drug location and 
overall entrapment efficacy. Several methods are now available for preparation of 
Liposomes. The cast film method is simple but the major drawback with MLVs 
prepared is the relatively low encapsulation in terms of aqueous space per mole of 
lipid. Dilute preparations of Liposomes with a low encapsulation efficiency is 
obtained, when solvent injection method is used. 
 
1.9 APPLICATIONS OF LIPOSOME 
 
During the past 40 years Liposomes have received attention from the scientific 
community and from the industry, due to the possibility of being a pharmaceutical 
carrier for numerous problematic drugs. This success to drive the present interest on 
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the field with more than 2000 papers and reviews per year, of which most of them are 
related to anticancer, anti-inflammatory and anti-microbial. 
 
1. Dinitroanilines when administered in the form of liposome shows better 
antimicrobial activity against leishmania than that of free drug. The 
improved antimicrobial activity is due to the engulfing of Liposomes by 
MPS cells (Mononuclear Phagocytic System) which is type of passive 
targeting. 
2. Rifamycin in the liposomal formulation has superior effect against 
tuberculi when compared to that of free drug. 
3. Doxorubicin can be encapsulated in liposome to reduce the serious side 
effects of the drug. 
 
Hence liposome can be used as the safer and more efficient drug 
delivery for many problematic entities. 
 
1.10   STABILITY OF LIPOSOMES 
 
The stability of Liposomes is of major concern in their development for 
pharmaceutical applications. A drug containing Liposomes can be unstable because of 
physical or chemical stability. The stability studies could be broadly covers under two 
main sections. 
 
Stability invitro mainly covers the stability aspects prior to the administration 
of the formulation and with regard to the stability of the constituted lipids. 
 
Stability invivo, which covers the stability aspects once the formulation, is 
administered via various routes of biological fluids. 
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Stability invitro mainly covers : 
I. Chemical degradation 
[a] Oxidation (Hunt C et al., 1981) 
The oxidative degradation of liposome can be prevented by 
following the below mentioned precautions  
1. Start with freshly purified lipids and freshly distilled 
solvent 
2. Avoid procedures which involves high temperature 
3. Carryout the manufacturing process in the absence of 
oxygen 
4. De-oxygenate aqueous solution in an inert atmosphere 
[b] Hydrolysis (Frfkjaer et al., 1984) 
            1.  Using lipid containing ether linkage instead of ester linkage 
2.  Sphingomyelin prevents invivo hydrolyses 
II. Physical degradation (Wong M et al., 1982) 
 Sedimentation, leaching of drugs aggregation or fusion. High 
manufacturing temperature and many other factors can induce this.  
Physical stability can be achieved by 
1. Manufacturing and storing at temperature below its transition temperature 
2. Adding 10% of P.A [Phosphatidic acid] or P.O to neutral liposome for 
providing negative pH. 
3. By cross linking membrane components covalently using gluteraldehyde 
fixation or polymerization of alkyne containing phospholipid. 
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Approaches that can be used to increase liposome stability involve efficient 
formulation and lyophilization. Formulation involves the selection of the appropriate 
lipid composition and concentration of bilayer, in addition to the aqueous phase 
ingredients such as buffer, antioxidants, metal-chelators and cryoprotectants. Charge 
inducing lipids such as Phosphotidyl glyceride be incorporated in to the liposome 
bilayer to decrease fusion, while cholesterol and sphingomyelin can be incorporated 
in formulation, in order to decrease the permeability and linkage of encapsulated 
drugs. 
1) Buffers at neutral pH can decrease hydrolysis 
2) Addition of antioxidants such as sodium ascorbate, can decrease oxidation  
3) Freeze-dried liposome formulations should incorporate a lipoprotectant 
like non-reducing disaccharides such as trehaloes and sucrose.    
 
1.11 CANCER CHEMOTHERPHY 
 
Cancer (Sydney. Basic clinical pharmacology (3
rd
 edition)) is a group of 
neoplastic diseases that occur in human of all age groups and races as well as in all 
animals species. The incidence, geographic distribution and behavior of specific types 
of cancer are related to multiple factors include sex, age, race, genetic predisposition 
and exposure to environmental carcinogen. 
 
Cancer is a disease of uncontrolled cell division, invasion and metastatic. It is 
generally considered to be due to the clonal expansion of a singe neoplastic cell. 
However there may be additional somatic leading to heterogeneous cell population. 
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Fig No:5   Understanding series of Cancer and normal Cell division 
 
 
Cancer chemotherapy has been under intensive development for the past 30 
years, resulting in cures of certain types of disseminated cancers that were previously 
fatal. Even patients with advanced disease have improved dramatically with 
chemotherapy. 
 
Mode of action of chemotherapeutic agents 
 
Most antineoplastic agents are regarded as “cell-cycle specific”. They act 
specifically on processes such as DNA synthesis, transcription, or the function of 
mitotic spindle. 
All slow growing and fast growing tumor cells display a similar pattern during 
the division. This may be characterized as follows: 
 
1. There is presynthetic phase 
2. The synthesis of DNA occurs 
3. An interval follows the termination of DNA synthesis, the post-synthetic 
phase. 
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4. Mitosis ensures, the G2 cell, containing a double complement of DNA, 
divides in to 2 daughter GI cells, may immediately re-enter to the cell 
cycle. 
 
Antitumor drugs are better at killing cells during DNA synthesis and active 
division. When a tumor is young, most of its cells are making DNA. This is defined as 
large growth function in this state, tumors are destroyed by drugs because the majority 
of their cells are making DNA and dividing. 
 
The major problems in cancer chemotheraphy are the toxic drugs effects on 
normal cells and the rapid clearance of the drug from the tumor cells. Usefull drugs 
without side effects do not at exist. Rapidly dividing normal cell such as hair follicles, 
cells lining the gastrointestinal tract and bonemarrow cells involved in the immune 
defence system are also destroyed by the present day chemotheraphy. Nausea, hair 
loss, increased susceptibility to infection and many others comprising a discouraging 
list. 
 
Liposomes: An ideal “Drug Carrier” for anticancer drugs 
 
Anticancer drugs (Sayed S. Daoud (1989)) are known to produce serious side 
effects to other healthy tissues. The more serious effects are myocardiopathy and 
pulmonary toxicity. Therefore targeting such type drugs to the cancerous cell is 
essential because these drugs are new for the treatment of different type of carcinomas 
effectively. Usually a therapeutically profitable target agent relationship is far from 
ideal and undesirable side effects are usually observed. The alternative is to use 
simple functional molecules which transport the drug to the specific site and release it 
to perform task. Liposomes are non-toxic, biodegradable microcapsule made up of 
one or multiple lipid bilayers membranes. 
 
Chemicals of interest can be entrapped inside the aqueous compartment of 
liposomes or can be incorporated in to the lipid bilayer. Covalent attachment of 
functional group to lipid molecules adds flexibility to liposomes. Liposomes have 
been proved a suitable vehicle for selective drug delivery and controlled drug release. 
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Important characteristics of drug carrier include protection of the encapsulated 
compound. Selective delivery of the entrapped material to specific tissues with 
minimal losses of drug during transit, regulation of the drug delivery rate, reduction of 
toxicity and removal of unused drug. All these function can co-exist in a single 
liposome preparation which makes it an ideal carrier of drug. Liposomes have proved 
to be suitable vehicles for antitumor drugs. 
                              
Figure No: 6 Accumulations of Lip osomes within Solid Tumors 
 
For example, doxorubicin which attacks dividing cells rapidly is used in the 
treatment of malignant tumors. Doxorubicin’s most serious side effect is progressive 
and irreversible damage to the heart. In addition the drug attacks hair follicles, 
intestinal cells and cells of immune system suppression. Laboratories in U.S, Canada 
and Israel have demonstrated in rodent, dogs that liposomal doxorubicin is an 
effective as the free drug but is several time less toxic to the heart. 
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If liposomes carrying a drug are exposed to oxygen radicals, the hydro 
peroxides formed will affect the permeability, behavior of the vesicles, thus causing 
premature release of the drugs targeting to a specific site. The targeting of compounds 
attached to proteins of polymers, which may be modified by radical attack, could 
provoke an adverse response thus amplifying the initial damage. Eg: In microbial 
infections with excessive phagocyte action or in disease involving redistribution and 
decompartmentalisation of iron. However optimization of a particular function is 
possible by modifying liposome composition, charge and size. 
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2. LITERATURE REVIEW 
 
Amarnath Sharma et al., described that liposomes are microparticulate 
lipoidal vesicles which are under extensive investigation as drug carriers for 
improving the delivery of therapeutic agents. In this they discussed the potential 
applications of liposomes in drug delivery with examples of formulation approved for 
clinical use, and the problems associated with further exploitation of these drug 
delivery systems. 
 
Antoneta et al., studied about cholesterol and other sterols are important 
components of biological membranes and are known to strongly influence the 
physical characteristics of lipid bilayers. Although this has been studied extensively in 
fully hydrated membranes, little is known about the effects of cholesterol on the 
stability of membranes in the dry state. 
 
Chieny et al., described the concept of designing specified delivery systems to 
achieve selective drug targeting. In this they compared between the conventional and 
targeting drug delivery systems. They described about advantages and limitations of 
target drug delivery systems. They described that the principle and rationale of drug 
targeting. 
 
Eugenia et al., reported the advantages and application of liposome with 
respect to anti-cancer, anti-inflammatory and anti-microbial agents. In this they 
described the advantages of the encapsulation macromolecules like enzymes into 
liposomes. In this study they incorporated the enzymes into liposomes by dried film 
hydration method and studied the therapeutic activity of enzymes. 
 
Fresta et al., described the preparation of various kinds of loaded of 5FU and 
reported on encapsulation efficacy, storage stability and fusogenic properties. They 
concluded that the most suitable liposome preparation was the SPL Vs that showed 
both better drug loading and stability parameters than others. 
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Ganesh et al., studied Inclusion of docetaxal in liposomal formulation has 
proved to be a good approach to eliminating the vehicle and improving the drug’s 
antitumor activity. We formulated docetaxel Liposomes containing 
phosphatidylcholine (soybean lecithin), cholesterol and various stabilizers by the 
dried thin film hydration method. Particle size analysis, drug content and entrapment 
efficiency in charged Liposomes were strongly affected by the different stabilizers, 
the stability of the lyophilized docetaxel Liposomes were evaluated after stored at 
40C and the room temperature for 3 months. The Liposomes stored at 40C were 
found to be stable for duration of 3months. Hence it can be concluded that stabilizers 
like Stearylamine and Dicetylphosphate along with cholesterol were suitable carrier 
for the preparation of liposomal docetaxel. 
 
Gautam Vinod et al., invented a long circulating non-pegylated liposomal 
doxorubicin hydrochloride composition for parenteral administration and a process 
for its preparation. The circulation time in Swiss albino mice is at least 25 times 
longer than conventional non-liposomal formulations. The non-pegylated liposomes 
are stable, exhibit low toxicity and have been found to be efficacious in different 
tumor models. 
 
Gregoiadis et al., reported the method of liposome formulation with lecithin 
(egg phosphatidly choline). In this they described about method to find out the 
percentage of drug loading and the usage of Triton-X 100 for the percentage of drug 
loading in liposome. They found that Triton-X 100 can be used to disrupt the lipid 
bilayer in liposome. Hence thereby the bound drug liberated out of the liposome.  
 
Harrington et al., described the slow process involved in the development of 
clinically relevant liposomal therapies and has show that, after concerted effort, a 
number of formulations are entering routine clinical practice. Indeed, in the near 
future, it is likely that more formulations of existing or novel cytotoxic agents will 
appear. In addition to this work, a number of approaches with the aim of enlarging the 
therapeutic repertoire of liposomal agents and improving their targeting potential are 
under investigation. Strategies employing liposomes to delivery radiosensitizers, 
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cytokines and immunomodulators have been described, as have attempts to increase 
tumour targeting with the use of hyperthermia and antibody-coated liposomes. 
Leptosomes are also receiving increased attention as potentially useful vehicles for 
the delivery of recombinant DNA constructs in the emerging science of gene therapy, 
although most of this work has focused on cationic liposomes which have very 
different pharmacokinetic profiles to the liposomes discussed in this review article. 
       
Jain et al., described the target drug delivery systems were likely to overcome 
much of the criticism of conventional dosage forms. They summarized that the 
optimized drug delivery that encompasses greater potency & greater effectiveness, 
lesser side effects and toxicity, better stability, low cost hence greater accessibility, 
ease of administration and best patient compliance. They also described about carriers 
used in targeted drug delivery systems. 
 
Jorge et al., reported the methods of liposomal formulation for encapsulating 
the enzyme (L-Asparaginase). In this study they formulated liposomes with natural 
phospholipids (egg yolk lecithin). They also described the method to conjugated the 
enzyme with palmitic acid to form palmitoyl-enzyme complex, which can further 
prolongs the circulation time of enzyme in general circulation without affecting the 
enzymatic activity i.e. from 2.88 hr to 23.7 hr. 
 
Lasic et al., described about the recent discoveries in the field of liposomes 
and latest application of liposomes. They described the usage of different types of 
liposomes and their advantages. In this they studied the efficacy of DNA 
encapsulation in liposomes. And in the treatment of colon carcinoma and AIDS 
related Kaposi sarcoma. From this study they confirmed the liposomes can be used as 
carrier for biological like RNA, DNA, etc. 
 
Luigi Cattel et al., synthesized a series of increasingly lipophilic pro drugs of 
gemcitabine by linking the 4-amino group with valeroyl, heptanoyl, lauroyl and 
stearoyl linear acyl derivatives. They studied their stability at storage, in plasma and 
with the lysosomal intracellular enzyme cathepsins and also studied incorporation of 
these lipophilic prodrugs in liposomes, where their encapsulation efficiency (EE) 
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closely depends on the length of the saturated 4-(N)-alee chain, the phospholipids 
chosen and the presence of cholesterol. A maximum EE for 4-(N)-steroyl-gemcitabine 
incorporated in DSPC/DSPG 9:1. This formulation was correlated with the highest 
stability in vitro and in vivo. Cytotoxicity of Gemcitabine prodrugs, free or 
encapsulated in liposomes, was between two- and sevenfold that of free gemcitabine. 
 
Marc Ostro et al., described the methods to reduce the dosage of drug with 
the help of liposomes and their potential advantages in different types of diseased 
states. In this they confirmed that liposomes are better dosage form than conventional 
dosage forms. They have also stated the drug can be targeted by active and passive 
targeting and the uses of both passive and targeting of liposomes. 
 
Mirant Ahmad et al., developed a well characterized novel lyophilized 
liposome-based paclitaxel (LEP-ETU) formulation that is sterile, stable and easy-to-
use. The mean particle size of the liposomes is about 150 nm before and after 
lyophilization, and the drug entrapment efficiency is greater than 90% stability data 
indicated that the lyophilized LEP-ETU was physically and chemically stable for at 
least 12 months at 2-8 and 25 8C. Moreover the formulation can diluted to about 0.25 
mg/ml without drug precipitation or change in particle size. In vitro drug release study 
in phosphate-buffered saline (PBS, pH 7.4) showed that less than 6%of the entrapped 
paclitaxel was released after 120 h, indicating that the drug is highly stable in an 
entrapped form at physiologic temperature. 
 
Monostoi et al., [2004] studied the stability and transdermal absorption of 
topical amphotericin B liposome formulation and found that the positively charged 
liposome might be the best formulation for AmB, dne to its higher stability than other 
formulations. 
 
Sayed Daoud et al., described the challenge of chemotherapy in this they 
discussed about liposomes in cancer therapy and liposomes: an ideal “drug carrier” 
for anti cancer drugs. They described the preclinical studies, clinical trials-phase 1 and 
2 and drug resistance of anthracyclines and also described alkylating agents and 
platinum compounds. 
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Soleiman Mohammadi-Samani et al., Described Cyproterone acetate (CA) 
has been loaded to liposome by solvent evaporation and thin film formation 
technique. The effects of some formulation variables such as temperature of organic 
solvent evaporation, rotary evaporator speed, volume of organic solvent, volume of 
balloon and temperature of hydrating buffer has been evaluated. Finally percutaneous 
absorption of CA from simple gel and liposomal formulations was assessed. The 
results showed that liposomal formulation has better penetration potential than 
conventional CA formulation (simple gel). 
          
Sydney et al., described the cancer chemotherapy in this they discussed 
incidence, geographic distribution and behavior of specific types of cancer. In that 
they described the mode of action, adverse effects, clinical use and dose 
administration of different chemotherapeutic agents. 
 
Tyrrell et al., described the general consideration and method of preparation 
of liposomes and also described about liposome- protein interaction and protein 
entrapment   liposomes. They summarized about uptake of liposomes in vivo and 
interaction of liposomes with cell culture and immunological aspects of liposomes. 
 
Uchegbu et al., attempted at anti-cancer drug targeting with doxorubicin 
(DOX), a DOX N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer showing 
tumour tropism in animals and designed to release DOX following intracellular 
cleavage by lysosomal enzymes is now in early clinical development. This 
macromolecular prodrug targets tumours by an enhanced penetration and retention 
(EPR) effect in which the leaky vasculature and decreased lymphatic drainage within 
tumours results in high intra tumoural levels of the drug which may be elevated 
further by increasing the polymer molecular weight. To reduce renal clearance of PKI 
and thus increase tumour accumulation, a non-ionic surfactant vesicle (niosome) 
formulation of PKI has been developed. Here we have studied the effect of method of 
preparation on PKI loading noisome, size, stability and DOX release. 
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Wollina et al., studied the usage of two drugs namely, doxorubicin and 
daunorubicin in liposomal formulation for treatment of skin cancer like cutaneous T-
cell lymphoma, malignant melanoma, AIDS related Kaposi’s sarcoma. They 
formulated liposomes with synthetic phospholipids and stabilizing agents like 
stearylamine and cholesterol. They also found that the efficacy of drug is improved in 
liposomal formulation than that of free drug. 
 
Xue Ming et al., studied site specific delivery of drugs and therapeutics can 
significantly reduce drug toxicity and increase the therapeutic effect. Transferring is 
one suitable ligand to conjugated to drug delivery systems to achieve site specific 
targeting, due to specific binding to transferring receptors, Administration of Tf-DOX 
to tumor-bearing mice could be used to deliver DOX effectively to the targeted site. 
This study indicated that the Tf-coupled PEG Liposomes could be as the targeted 
carriers to facilitate the delivery of the encapsulated anticancer drugs in to tumor cells 
by receptor-mediated way.  
 
Yousefi et al., An improved pegylated liposomal formulation of docetaxel has 
been developed with the purpose of improving the docetaxel solubility without any 
need to use tween80 that is responsible for hypersensitivities following 
administration. Liposomes all had spherical shape with size of 130–160 nm. The most 
important finding of this study is that pegylated Liposomes were prepared with 
significant increase in docetaxel encapsulation efficiency and stability of the 
formulation in comparison with last reports on docetaxel Liposomes. In vitro release 
studies revealed that such a formulation could be stable in the blood circulation and 
meet the requirements for an effective drug delivery system. 
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3. AIM AND PLAN OF WORK 
       
Liposomes have been used to target drug to specific organs, delay the loss of 
rapidly cleared, drugs, enhances therapeutic potency and offer a host of the other 
advantages. 
Doxorubicin hydrochloride is one of the most commonly used cytotoxic 
anthracycline antibiotics used in cancer chemotherapy and has been shown to have 
activity against a wide variety of neoplasms. 
 Conventional compositions of doxorubicin hydrochloride are available as 
freeze-dried product (or) as a solution of doxorubicin hydrochloride in water. Both 
these products have been associated with a number of toxicities when administered 
intravenously. Severe myelosupression, nausea, vomiting, alopecia, mucosistis & 
cardio toxicity, limits the use of Doxorubicin Hcl. It also causes extravasations & 
necrosis at the site of injection. 
To overcome these problems, an alternative approach is needed. In the present 
study doxorubicin Hcl liposomes are formulated using various biolipids and 
Stabilizers (Positive and Negative) to check effect of drug loading and particle size. 
Several approaches has taken in an effort to increase the circulation time of liposome 
by coating the liposomal surface with a hydrophilic polymer such as polyethylene 
glycol (PEG) to prevent adsorption of various blood plasma proteins to the liposome 
surface. These liposomes appeared to reduce some of the toxic effects caused by the 
release of their contents, but have new toxic effects appeared like skin toxicity 
generally known as “Hand-Foot Syndrome” and the presence of large molecules 
(PEG) on the liposomal surface may reduce the interaction of liposomal with cells & 
hinder entry of liposomes in to tumor tissue.   
   
Thus, these remains a need for stable, long circulating liposomes that do not 
cause such deleterious effects such as the “Hand-Foot Syndrome” as well as methods 
of manufacturing such liposomes & composition based on them. The present 
formulation meets this need, and testing the effect of stabilizers on particle size 
analysis, percent free drug, Assay, In-vitro drug release studies, release kinetics & 
stability studies. 
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IT WAS PLANNED TO CARRY OUT THE PRESENT STUDY AS 
FOLLOWS: 
 
STAGE 1: 
 
1. Preformulation  studies 
a. Standard calibration curve of Doxorubicin hydrochloride in UV 
b. Compatibility studies 
STAGE 2: 
 
1. Preparation of Plain Liposomes with Ammonium sulphate and stabilizers. 
2. Preparation of drug loaded liposomes with Stabilizers by Dried Thin Lipid 
Film Hydration Technique. 
STAGE 3:  
 
1. Physical characterization of liposomes 
a. Particle size analysis 
b. Zeta potential 
  c. Scanning Electron Microscopy 
d. Polydispersity index 
STAGE 4: 
 
1. In vitro characterization 
a. Percent free drug  
b. Assay 
c. Study on in vitro drug release. 
d. Release kinetics 
 
STAGE 5: 
 
1. Short term stability studies 
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4. PROFILE 
 
4.1DRUG PROFILE: 
 
Doxorubicin hydrochloride: 
 
Doxorubicin is a drug used in cancer chemotherapy, it is an anthracycline 
topoisomerase inhibitor isolated from streptomyces peucetius var. caesius. 
 
Doxorubicin is commonly used in the treatment of a wide range of cancers, 
including hematological malignancies, many types of carcinoma, and soft tissue 
sarcomas (Wikipedia). 
Chemistry 
                                 
                       
 
 
 
 
 
 
 
STRUCTURE OF DOXORUBICIN HYDROCHLORIDE 
 
 
 
 
 
 
 
 
 
         Systemic (IUPAC) name 
(8S, 10S)-10-(4-amino-5-hydroxy-6-
methyl-tetrahydro-2H-pyran-2-yloxy) 
-6, 8, 11-trihydroxy-8-(2hydroxyacetyl) 
-1-methoxy-7, 8, 9, 10-
tetrahydrotetracene 
-5, 12-dione 
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Molecular formula: C27H29NO11 
Molecular weight: 579.98gm. 
Melting point: 204-205
o
 C. 
Physics description: Red crystalline powder. 
Solubility: Sparingly soluble in cold water and Insoluble in diethyl ether. 
Bioavailability: 5% (Oral). 
Half-life:12–18.5 hours 
 
Mechanism of action: 
 
The exact mechanism of action of doxorubicin is complex and still somewhat 
unclear, though it is thought to interact with DNA by intercalation. Doxorubicin is 
known to interact with DNA by intercalation and inhibition of 
macromolecular biosynthesis. This inhibits the progression of the 
enzyme topoisomerase II, which relaxes super coils in DNA for transcription. 
Doxorubicin stabilizes the topoisomerase II complex after it has broken the DNA 
chain for replication, preventing the DNA double helix from being resealed and 
thereby stopping the process of replication. 
 
The planar aromatic chromophore portion of the molecule intercalates 
between two base pairs of the DNA, while the six-membered daunosamine sugar sits 
in the minor groove and interacts with flanking base pairs immediately adjacent to the 
intercalation site, as evidenced by several crystal structures. 
 
Pharmacokinetics 
 
The plasma pharmacokinetics of Doxorubicin Hydrochloride were evaluated 
in 42 patients with AIDS relative Kaposi’s sarcoma (KS) who received single doses 
of 10 or 20mg/m2 administered by a 30-minute infusion. Twenty –three of these 
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patients received single doses of 10 and 20 mg/m2 with a 3-week wash-out period 
between doses. 
 
Doxorubicin Hydrochloride linear pharmacokinetics is over the range of 10 to 20 
mg/m2. Disposition occurred in two phases after Doxorubicin hydrochloride 
administration, with a relatively short first phase (5 hours) and a prolonged second 
phase (55 hours) that accounted for the majority of the area under the curve (AUC). 
 
Distribution: 
 
In contrast to the pharmacokinetics of doxorubicin, which displays a large 
volume of distribution, ranging from 700 to 1100 L/m2, the small steady state volume 
of distribution of Doxorubicin Hydrochloride shows that Doxorubicin Hydrochloride 
is confined mostly to the vascular fluid volume. Plasma protein binding of 
Doxorubicin Hydrochloride has not been determined; the plasma protein binding of 
doxorubicin is approximately 70%. 
 
Metabolism: 
 
Doxorubicinol, the major metabolites of doxorubicin, was detected at very low 
levels (range: of 0.8 to 26.2 ng/mL) in the plasma of patients who received 10 or 20 
mg/m2 Doxorubicin Hydrochloride. 
 
Excretion: 
 
The plasma clearance of Doxorubicin Hydrochloride was slow, with a mean 
clearance value of 0.041 L/h/m
2
 at a dose of 20 mg/m
2
. This is in contrast to 
doxorubicin, which displays a plasma clearance value ranging from 24 to 35 L/h/m
2
. 
 
Because of its slower clearance, the AUC of Doxorubicin Hydrochloride, 
primarily representing the circulation of liposome-encapsulated doxorubicin, is 
approximately two to three orders of magnitude larger than the AUC for a similar 
dose of conventional doxorubicin HCL as reported in the literature. 
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Tissue distribution in patients with Kaposi’s sarcoma: 
 
Kaposi’s sarcoma lesions and normal skin biopsies were obtained at 48 and 98 
hours pos infusion of 20 mg/m
2
 Doxorubicin hydrochloride in 11 patients. The 
concentration of Doxorubicin Hydrochloride in KS lesions was a median of 19 (range, 
3-53) times higher than in normal skin at 48 hours post treatment; however, this was 
not corrected for likely difference in blood content between KS lesions and normal 
skin. The corrected ratio may lie between 1 and 22 times. Thus, higher concentrations 
of Doxorubicin Hydrochloride are delivered to KS lesions than to normal skin. 
  
CLINICAL STUDIES 
 
Ovarian cancer: 
 
Doxorubicin Hydrochloride was studied in three open-label, single-arm, 
clinical studies of 176 patients with metastatic ovarian cancer. One hundred forty-five 
(145) of these patients were refractory to both paclitaxel- and platinum-based 
chemotherapy regimens. Refractory ovarian cancer is defined as disease progression 
while on treatment, or relapse within 6 months of completing treatment. Patients in 
these studies received Doxorubicin Hydrochloride at 50  mg/m
2
 infused over one hour 
every 3 or 4 weeks for 3-6 cycles or longer in the absence of dose-limiting toxicity or 
progression of disease. 
 
Side effects: 
 
The following adverse reactions are discussed in more detail in other sections 
of the labeling. 
 
 Cardiac Toxicity 
 Infusion reactions  
 Myelosuppression  
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The most common adverse reactions observed with Doxorubicin 
Hydrochloride are 
 
 Asthenia 
 Fatigue 
 Fever 
 Nausea 
 Stomatitis 
 Vomiting 
 Diarrhea 
 Constipation 
 Anorexia 
 Hand-foot syndrome 
 Rash and neutropenia 
 Thrombocytopenia and anemia. 
DOSAGE AND ADMINISTRATION 
 
Liposomal encapsulation can substantially affect a drug’s functional properties 
relative to those of the unencapsulated drug. Therefore do not substitute one drug for 
the other. 
 
Do not administer as a bolus injection or an undiluted solution. Rapid infusion 
may increase the risk of infusion-related reactions. Doxorubicin Hydrochloride must 
not be given by the intramuscular or subcutaneous route. 
 
Doxorubicin Hydrochloride should be considered an irritant and precautions 
should be taken to avoid extravasations. With intravenous administration of 
Doxorubicin Hydrochloride, extravasation may occur with or without an 
accompanying stinging or burning sensation, even if blood returns well on aspiration 
of the infusion needle. If any signs or symptoms of extravasation have occurred, the 
infusion should be immediately terminated and restarted in another vein. The 
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application of ice over the site of extravasations for approximately 30 minutes may be 
helpful in alleviating the local reaction. 
 
Ovarian Cancer: 
Doxorubicin Hydrochloride should be administered intravenously at a dose of 
50 mg/m2 at an initial rate of 1 mg/min to minimize the risk of infusion reactions. 
 
Kaposi’s sarcoma: 
Doxorubicin hydrochloride should be administered intravenously at a dose of 
20 mg/m2. An initial rate of mg/min should be used to minimize the risk of infusion-
related reactions. 
 
Multiple Myeloma: 
Bortezomib is administered at a dose of 1.3 mg/m
2
 as intravenous bolus on 
days 1, 4, 8 and 11, every three weeks. Doxorubicin Hydrochloride 30 mg/m
2
 should 
be administered as a 1-hr intravenous infusion on day 4 following bortezomib. 
 
Dose Modification Guidelines: 
Doxorubicin Hydrochloride exhibits nonlinear pharmacokinetics at 50 mg/m
2
; 
therefore, dose adjustments may result in a non-proportional greater change in plasma 
concentration and exposure to the drug. 
 
Patients should be carefully monitored for toxicity. Adverse reactions, such as 
HFS, hematologic toxicities, and stomatitis may be managed by dose delays and 
adjustments. Following the first appearance of a grade 2 or higher adverse reactions, 
the dosing should be adjusted or delayed as described in the following tables. Once 
the dose has been reduced, it should not be increased at a later time. 
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4.2 LIPID PROFILE: 
 
Soy lecithin 
Lecithin (Wikipedia. Org/wiki/lecithin) is a group of yellow-brownish fatty 
substance occurring in animal and plant tissues, and in egg yolk, composed of 
phosphoric acid, choline, fatty acids, glycerol, glycolipids, triglycerides, and 
phospholipids (e.g., Phosphatidylcholine, phosphatidylethanolamine and 
phosphatidylinositol). However, lecithin is sometimes used as a synonym for pure 
phosphatidylcholine, a phospholipids that is the major component of its phosphatide 
fraction. It may be isolated either from egg yolk (in Greek lekithos or from soy beans, 
from which it is extracted chemically (using hexane)) or mechanically. 
  
Lecithin is used as a food supplement and for medical uses. 
 
Chemistry: 
Lecithin used for the study is composed of different type of phospholipids like 
phosphatidylcholine, phosphatidyletanolamine and phoaphatidyllinositol and 
lysophophatidylcholine cholesterol. The structure of basic phospholipids molecule is 
given below.  
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Description: 
 
Colour: Yellowish brown 
 Molecular Formula: C36H72NO8P  
 Molecular Weight: 677.93gm 
Consistency: Agglomerates 
Iodine value: 85-95 
Peroxide value: n.m.t 3 
 
Solubility: 
Lecithin is soluble in both aqueous and organic phase. Hence it can be used as 
emulsifier in food industry and it is also capable of forming vesicles thereby it is used 
in pharmaceutical industry. It gives clear or slightly opalescent solutions with both 
phases. 
 
4.3 Cholesterol: 
 
Cholesterol is a waxy steroid of fat that is manufactured in the liver or intestines. 
It is used to produce hormones and cell membranes and is transported in the blood 
plasma of all mammals. It is an essential structural component of mammalian cell 
membranes. It is required to establish proper membrane permeability and fluidity. In 
addition cholesterol is an important component for the manufacture of bile acids, 
steroid hormones and vitamin D. 
 
Description: 
 
White or faintly yellow, almost odorless, pearly leaflets, needles, powder and 
granules. On prolonged exposure to light and air cholesterol acquires a yellow to tan 
color. 
  
                                                                                                                   
Profiles 
 
Dept., of Pharmaceutics, The Erode College of Pharmacy & Research Institute, Erode Page 46 
 
CHEMISTRY: 
 
 
                                               IUPAC name 
                                      (3β)-Cholest-5-en-3-ol 
 
Synonyms: Cholestrin  
Molecular Formula:  C27H46O          
Molar mass:  386.65 g/mol 
Appearance:  white crystalline powder 111 
Density: 1.052 g/cm
3
 
Melting point:  148-150
o
C 
Boiling point:   360
o
C (decomposes) 
Solubility in water:   0.095 mg/L (30
o
C) 
Solubility: Soluble in acetone, benzene, chloroform, ethanol, ether, hexane, 
isopropyl myristate and methanol. 
 
Metabolism and Excretion: 
Cholesterol is oxidized by the liver in to a variety of bile acids. These in turn 
are conjugated with glycine, taurine, glucuronic acid, or sulphate. A mixture of 
conjugated and non-conjugated bile acids along with cholesterol itself is excreted 
from the liver in to the bile. Approximately 95% of the bile acids are reabsorbed from 
the intestine and the remainder lost in the feces. The excretion and reabsorption of 
bile acids forms the basis of the Entero-hepatic circulation which is essential for the 
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digestion and the absorption of dietary fats. Under certain circumstances, when more 
concentrated, as in the gallbladder, cholesterol crystallizes and is the major 
constituent of most gallstones, although lecithin and bilirubin gallstones also occur 
less frequently. 
 
Function: 
Cholesterol is required to build and maintain cell membranes; it regulates 
membrane fluidity over a wide range of temperatures. The liver produces about 1 
gram of cholesterol per day, in bile. The hydroxyl group on cholesterol interacts with 
the polar. Head groups of the membrane phospholipids and Sphingolipids, while the 
bulky steroid and the hydrocarbon chain is embedded in the membrane, alongside the 
nonpolar fatty acid chains of the other lipids. Bile which is stored in the gallbladder 
and helps digest fats is important for the absorption of the fat soluble vitamins, 
vitamins A, D, E and K. It also reduces the permeability of the plasma membrane. In 
myelin, it envelops and insulates nerves, helping greatly to conduct nerve impulses.  It 
also reduces the permeability of the plasma membrane to protons (Positive hydrogen 
ions) and sodium ions. 
 
Stability and storage Condition: 
Cholesterol is stable and should be stored in a well closed container, protected 
from light. 
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EXCEPIENTS PROFILE: 
 
4.4 STEARYL AMINE: 
 
Synonyms : 1-Amonooctadecane, Octadecylamine, n-Stearylamine, 1-
Octadecanamine,  Octadecylamine, Monooctadecylamine, n- Octadecylamine. 
 
Structure: 
                                          
 
Molecular formula: CH3 (CH2)17NH2  
Molecular weight: 269.52gm. 
Classification: Amines / Surfactants 
Physical state: White to off-white solid 
Melting Point: 47-53
0
C 
Boiling Point: 232
0
C 
Solubility in water: Practically insoluble 
Stability: Stable under ordinary conditions           
Applications: 
 Cationic surfactants (disinfectants, fungicides, germicide, leveling agents, 
hair rinse bases, wood preservatives, textile softeners, dyeing auxiliaries, 
ore flotation. pigment grinding aids. anticaking agents)  
 Amphoteric surfactants and Amine oxides (antistatic agent, textile 
scouring agent, ingredient for low irritation shampoo, liquid detergent, 
foam booster, oil recovery agent)  
 Corrosion inhibitors and asphalt emulsifier  
 Dispersants, lubricants, water treatment agents. 
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 Fatty amine products are used as a dispersing agent or internal/external 
lubricant for benefits in polymer production of to facilitate and stabilize 
the dispersion of solid compounding materials to enhance processability, 
to decrease friction and abrasion of the polymer surface, and to contribute 
color stability and corrosion prevention.  
 
4.5 DICETYL PHOSPHATE: 
 
Synonyms: 1-Hexadecanol, hydrogenphosphate; bis (hexadecyl) phosphate; 
Dicetylhydrogenphosphate; di-n-hexadecylphosphate; phosphoric acid Dihexadecyl 
ester; dihexadecyl hydrogen phosphate; dihexadecyl phosphate; Dicetyl phosphate. 
 
Structure: 
                     
 
 
Molecular Formula: C32H67O4P  
Molecular Weight: 546.85 
Physical state: White powders  
Melting Point: 74-75
0
C 
Storage temp:  -20
0
C 
Applications: 
 Anionic surfactant. 
 Corrosion inhibitors and asphalt emulsifier  
 Dispersants, lubricants, water treatment agents.  
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5. MATERIALS AND INSTRUMENTS 
 
Materials  
 
The materials used in the present investigation were either AR/LR grade or the 
best possible pharma grade. 
 
Table No:1   List of Chemicals 
                         
 
S.No Ingredients 
 
Manufactures 
     1. Doxorubicin hydrochloride 
 
Sterling biotech, china. 
     2. Soybean lecithin 
 
Lipoid  Pvt. Ltd., Mumbai. 
     3. Cholesterol 
 
Lipoid  Pvt. Ltd., Mumbai. 
     4. Dicetyl phosphate 
 
Sigma Aldrich, Mumbai. 
     5. Stearylamine 
 
Sigma Aldrich, Mumbai.                                                                                                                                                                                                                                                                                                                                                                                                                            
     6. Ammonium sulphate 
 
Triveni chemicals, Mumbai. 
     7. Sucrose 
 
Triveni chemicals, Mumbai. 
     8. Histidine 
 
Merck chemicals, Mumbai. 
     9. Chloroform 
                                                        
Fisher scientific, Mumbai. 
. 
    10. Sodium hydroxide 
 
Merck chemicals, Mumbai. 
    11. Triton X-100 
 
Merck chemicals, Mumbai. 
    12. Acetonitrile 
 
Merck chemicals, Mumbai. 
    13. Methanol 
 
Merck chemicals, Mumbai. 
    14. Sodium lauryl sulphate 
 
Merck chemicals, Mumbai. 
    15. Isopropyl alcohol 
 
Merck chemicals, Mumbai. 
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Equipments and Instruments: 
 
1. UV- Visible spectrophotometer (PerkinElmer’s) 
 
2. Infra Red spectroscopy (Bruker) 
 
3. Rotary vacuum evaporator (Buchi) 
 
4. Homogenizer (Panda) 
 
5. Peristaltic pump (Electro lab) 
 
6. Electronic balance (Sartorius) 
 
7. Centrifuge (Remi Instruments) 
 
8. Bath Sonicator  
 
9. Electronic Microscope (Motic) 
 
10. HPLC (LC20AD, Shimadzu) 
 
11. Magnetic stirrer (Remi Instruments) 
 
12. Zeta Sizer version 6.00(Malvern) 
 
13. Scanning Electron Microscopy(Field Instruments) 
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6. METHODOLOGY 
 
6.1STANDARD CALIBRATION CURVE 
 
Standard calibration curve of doxorubicin hydrochloride was developed using 
phosphate buffer pH 7.4 and estimated by UV-Visible spectrophotometer at 254nm. 
 
6.1.1 General Procedure for the preparation of calibration curve by UV 
 
A stock solution of (1mg/ml) of standard drug was prepared, later required 
dilutions were made with a phosphate buffer pH 7.4. To a series of 10ml volumetric 
flasks aliquots standard solutions were taken and the volume was made up using a 
phosphate buffer pH 7.4. The absorbance of these solutions was measured at 
respective wave length of maximum absorbance, using 1cm quartz cuvette in UV- 
Visible spectrophotometer. Absorbance values were plotted against respective 
concentration to obtain standard calibration curve.  
 
6.2 COMPATIBILITY STUDIES 
  
IR spectroscopy can be used to investigate and predict any physicochemical 
interactions between different components in a formulation and therefore it can be 
applied to the selection of suitable chemically compatible excipients. 
 
The aim of the present study was to test, wether there is any interactions 
between the carriers and drug; The following IR spectroscopy were recorded 
     
 Doxorubicin hydrochloride. 
 Soybean lecithin. 
 Cholesterol. 
 Mixture of phospolipid and cholesterol. 
 Mixture of phospolipid, cholesterol, drug and Stearylamine. 
 Mixture of phospolipid, cholesterol, drug and Dicetyl phosphate. 
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One part of the sample and three parts of potassium bromide were taken in a 
mortar and triturated. A small amount of triturated sample was taken in to a pellet 
maker and was compressed at 10kg/cm
2
 using hydraulic press. The pellet was kept on 
to the sample holder and scanned from 4000cm
-1
 to 400cm
-1
 in Bruker IR 
spectrophotometer. Then it was compared with original spectra. 
 
IR spectra was compared and checked for any shifting in functional peaks and 
non-involvement of functional group. From the spectra it is clear that there is no 
interaction between the selected carriers, drug and mixtures. Hence the selected 
carrier was found to be compatible in entrapping the selected doxorubicin 
hydrochloride with carriers without any mutual interactions. 
 
6.3 PREPARATION OF DOXORUBICIN LIPOSOMES 
 
6.3.1 Procedure for the preparation of doxorubicin liposome (Xue Ming Li et al., 
2009) 
 
The preparation of liposomes with Soybean lecithin was prepared by dried 
thin film hydration technique using rotary evaporator. 
 
Accurately weighed quantities of Soy lecithin, cholesterol, Stearylamine and 
Dicetylphosphate are dissolved in chloroform and rotated in a rota-vap by applying 
vaccum of about 25mmHg at 25
0
c, until it forms a thin film. Required quantities of 
ammonium sulphate and sucrose (0.3%) are dissolved in W.F.I and it is added to the 
above thin film in R.B flask and rotated until it forms a milky white suspension. The 
above solution is homogenized for 15 cycles to reduce particle size of liposomes. The 
above solution is undergone for 25 cycles of dialysis, by using sucrose solution (10%) 
to remove free ammonia and sulphate from the lipid solution. Drug solution is 
prepared by adding the required quantities of Drug and Histidine in a W.F.I and pH is 
adjusted to 6.4 to 6.7 and this drug solution is added to the solution in a R.B flask 
(lipid solution) and rotated for 1hr. 
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In-process Checks: 
 
RPM: 65-70rpm (Film formation), 50-55rpm (Hydration), 60-65rpm (Drug 
Loading). 
 
Temperature: 40-45°C (Film formation), 65-70°C (Hydration), 65°C (Drug 
Loading). 
 
The composition and ratios of lecithin, cholesterol and stabilizers for different 
types of Liposomes were mentioned in Table No: 7 and 8. 
 
6.4 PHYSICAL CHARACTERIZATION OF LIPOSOMES 
 
All the liposomal formulation was evaluated by studying their 
physicochemical properties like 
 
 Particle size analysis  
 Polydispersity index 
 Zeta potential analysis 
 SEM analysis 
 
6.4.1 Determination of particle size distribution 
 
Determination of average vesicle size of doxorubicin hydrochloride liposomes 
with carrier was very important characteristic. It was carried out by using MALVERN 
INSTRUMENTS, STARTECH LABS PVT. LTD. 
 
  
                                                                                                       
Methodology 
 
Dept., of Pharmaceutics, Erode college of pharmacy and research institute, Erode Page 55 
 
6.4.2 Polydispersity Index: 
 
Polydispersity was determined according to the equation, 
 
Polydespersity   =   D (0.9) - D (0.1) / D (0.5) 
 
Where, 
D (0.9) corresponds to particle size immediately above 90% of the sample. 
D (0.5) corresponds to particle size immediately above 50% of the sample.  
D (0.1) corresponds to particle size immediately above 10% of the sample. 
 
6.4.3 SCANNING ELECTRON MICROSCOPY 
 
Determination of surface morphology (roundness, smoothness and formation 
of aggregates) of doxorubicin hydrochloride Liposomes with carrier was carried out 
by scanning electron microscopy (SEM). Samples for by SEM were mounted on 
metal studs and were magnified to X 2000. 
 
6.4.4 ZETA POTENTIAL ANALYSIS 
 
Zeta potential is a physical property which is exhibited by any particle in 
suspension. It can be used to optimize the formulations of suspensions and emulsions. 
Knowledge of the zeta potential can reduce the time needed to produce trial 
formulation. It is also an aid in predicting long-term stability. The magnitude of the 
zeta potential gives an indication of the potential stability of the colloidal system. If 
all the particles in suspension have a large negative or positive zeta potential then they 
will tend to repeal each other and there will be no tendency for the particles to come 
together. However, if the particles have low zeta potential values then there will be no 
force to prevent the particles coming together and flocculating. 
 
The significance of zeta potential is that its value can be related to the stability 
of colloidal dispersions. So, colloids with high zeta potential (negative or positive) are 
electrically stabilized while colloids with low zeta potentials tend to coagulate or 
                                                                                                       
Methodology 
 
Dept., of Pharmaceutics, Erode college of pharmacy and research institute, Erode Page 56 
 
flocculate. A value of 25mV (positive or negative) can be taken as the arbitrary value 
that separates low-charged surfaces from high-charged surfaces. The zeta potential 
was analyzed by MALVERN ZETASIZER in INDIAN INSTITUTE OF CHEMICAL 
TECHNOLOGY. 
 
 6.5 IN VITRO CHARACTERIZATION 
 
6.5.1Estimation of free ammonia: 
Added 1ml of lipid solution to 1ml of barium chloride solution and mixed 
together in a centrifuge tube and centrifuged for 10 minutes at 5000rpm, it forms a 
precipitate of barium sulphate, the formed precipitate is dried and weight of barium 
sulphate is noted. 
 
Free ammonia = weight of barium sulphate ×0.56590   
6.5.2 Percent free drug: (Howard G et al., 1977) 
Measure the absorbance of solution at 590nm using sucrose Histidine solution 
as blank. 
1. Transferred 0.1ml of sample to a 20ml stoppered test tube, add 8ml of 
Sucrose-Histidine solution to it, mix well, measure the absorbance at 
590nm using calibrated UV spectrophotometer. Transfer the solution 
from the cell to test tube (A1). 
2. To the above test tube containing solution, added 1ml sodium 
hydroxide solution, mix well measure the absorbance at 590 nm using 
UV transfer the solution from the cell to test tube (A2) 
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3. To the above test tube containing solution, add 1ml of Triton X-100 
solution, mix well measure the absorbance at 590 nm using calibrated 
UV (A3)  
   Percent Free Doxorubicin Hcl = [(A2×1.125) –A1/A3×1.25] × 100 
6.5.3 Doxorubicin Hcl Assay (Howard G et al., 1977) 
A standard and sample solution were prepared, Inject separately 20 microlitre 
of the standard and sample solution in chromatographic condition and record the 
chromatogram. Calculate the content of drug per ml in liposomal injection as follows. 
                 
           Assay= A/B×W/200×5/50×C/100×100-D/100×50/5×100/5 
Where, 
A = Area corresponding to Doxorubicin Hcl in sample. 
B = Area corresponding to Doxorubicin Hcl in working standard. 
C = % purity of Doxorubicin Hcl in working standard. 
 D = % water content of working standard. 
 W = Weight of working standard in mg. 
 
Chromatographic conditions: 
Column           : C18 BDS (250×4.6mm) 
Mobile phase  :  Buffer + Acetonitrile + Methanol (47ml+48ml+ 5ml) 
Buffer             :  2.8% w/w sodium lauryl sulphate + 2.3% w/v  
   Phosphssoric Acid. 
Wave length   : 254nm. 
Flow rate        :  1.7sml/mn. 
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Solvent           : Acidified IPA (90mlIPA+ 0.68ml Hcl+ Make up to   
                                 100ml with water) 
6.5.4 In vitro dissolution studies of Doxorubicin hydrochloride liposome 
 
The in vitro release of drug from the liposomal formulation was carried out by 
using dialysis membrane employing in two sides open ended cylinder. 
 
4 ml of liposomal suspension containing known amount of drug was placed in 
a dialysis membrane previously soaked overnight. The two sides open cylinder was 
placed in 200ml of PBS (pH 7.4), maintained at 37
o
 C and stirred with the help of a 
magnetic stirrer. Aliquots (4ml) of release medium were withdrawn at different time 
intervals and the sample was replaced with fresh PBS (pH 7.4) to maintain constant 
volume. 1 ml of acetonitrile was added to each aliquot to precipitate the lipids and 
dissolve the entrapped Doxorubicin hydrochloride and then the samples were 
analyzed by UV spectrophotometry at a λ max of 254nm. 
 
6.5.5 Release kinetics (Harris shoaib et al., 2006) 
 
To analyze the in vitro release data various kinetic models were use to 
describe the release kinetics. The zero order rate Eq. (2) describes the systems where 
the drug release rate is independent of its concentration. The first order Eq. (3) 
describes the release from system where release rate is concentration dependent. 
Higuchi (1963) described the release of drugs from insoluble matrix as a square root 
of time dependent process based on Fickian diffusion. 
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The results of in vitro release profile obtained for all the formulations were 
plotted in modes of data treatment as follows: 
1. Zero - order kinetic model – Cumulative % drug released versus time. 
2. First – order kinetic model – Log cumulative percent drug remaining 
versus time. 
3. Higuchi’s model – Cumulative percent drug released versus square 
root of time. 
4. Korsmeyer equation / Peppa’s model – Log cumulative percent drug 
released versus log time. 
 
a. Zero order kinetics: 
 
       Zero order release would be predicted by the following equation: 
                                    
                                    At = A0 – K0t 
                   Where  
                            At = Drug release at time‘t’ 
                           A0 = Initial drug concentration. 
                           K0 = Zero- order rate constant (hr
-1
)   
 
When the data is plotted as cumulative percent drug release versus time, if the 
plot is linear then the data obeys Zero – order kinetics and its slope is equal to Zero 
order release constant K0. 
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b. First order kinetics: 
   First - order release could be predicted by the following equation: 
                    
                                      Log C = log C0 – Kt / 2.303 
                    Where, 
                               C = Amount of drug remained at time‘t’ 
                              C0  = Initial amount of drug. 
                               K = First - order rate constant (hr
-1
). 
 
When the data plotted as log cumulative percent drug remaining versus time, 
yields a straight line, indicating that the release follow first order kinetics. The 
constant ‘K1’ can be obtained by multiplying 2.303 with the slope value. 
 
c. Higuchi’s model: 
 
Drug release from the matrix devices by diffusion has been described by 
following  
Higuchi’s classical diffusion equation: 
  
Q = [DЄ / τ(2A – ЄCs ) Cst]
1/2
 
 
Where,               
Q = Amount of drug release at time‘t’ 
D = Diffusion coefficient of the drug in the matrix. 
A = Total amount of drug in unit volume of matrix. 
Cs = Solubility of drug in the matrix. 
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Є = Porosity of the matrix. 
τ = Tortuosity. 
t = Time (hrs at which q amount of drug is released. 
Above equation can be simplified as if we assumes that ‘D’, ‘Cs’ and ‘A’ are 
constant. Then equation becomes: 
Q = Kt
1/2 
When the data is splitted according to equation i.e. cumulative drug release 
versus square root of time yields a straight line, indicating that the drug was released 
by diffusion mechanism. The slope is equal to ‘K’ (Higuchi’s 1963). 
 
d. Korsmeyer equation / Peppa’s model: 
 
To study the mechanism of drug release from the liposomal solution, the 
release data was also fitted to the well-known exponential equation (Korsmeyer 
equation/ Peppa’s law equation), which is often used to describe the drug release 
behavior from polymeric systems. 
 
Mt / Mα = Kt
n 
Where, 
Mt / Mα = The fraction of drug released at time‘t’.     
K = Constant incorporating the structural and geometrical 
characteristics of the  drug / polymer system. 
n = Diffusion exponent related to the mechanism of the release. 
 
Above equation can be simplified as follows by applying log on both sides, 
Log Mt / Mα = Log K+ n Log t 
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Mechanism of drug release 
 
Table 2: Diffusion exponent and solute release mechanism for cylindrical shape 
S.No Diffusion  Exponent (n) Overall solute 
diffusion mechanism 
1.   
      0.45 
 
    Fickian diffusion 
2.  
0.45<n<0.89 
 
    Anomalous (non-Fickian)      
diffusion 
3.  
      0.89  
 
    Case-II transport 
4.  
    n>0.89 
   
    Super case-II transport 
 
6.6 SHORT TERM STABILITY STUDIES 
 
The stability of a pharmaceutical delivery system may be defined as the 
capability of a particular formulation, in a specific container. The short-term stability 
was conducted to monitor physical and chemical stabilities of the liquid form of 
doxorubicin hydrochloride liposomal formulations at 40
o
C and room temperature for 
up to three months. The stability parameter, such as Assay was determined as function 
of the storage time. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
RESULTS 
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7. RESULTS 
 
TABLSES 
Table No: 3 Standard readings of Doxorubicin hydrochloride in UV 
  
 
     
 
 
 
 
 
 
 
 
 
 
Graph No: 1 Standard graph of Doxorubicin hydrochloride in phosphate buffer 
of   pH 7.4. 
 
 
y = 0.0179x
R² = 0.9995
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S. No. Concentration 
(µg/ml) 
Absorbance at 254nm 
1. 0 0 
2. 10 0.184 
3. 20 0.348 
4. 30 0.526 
5. 40 0.721 
6. 50 0.901 
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Spectra No: 1 FTIR of Doxorubicin Hcl 
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Spectra No: 2 FTIR of Soy lecithin 
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Spectra No: 3 FTIR of Cholesterol 
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Spectra No: 4 FTIR of Soy lecithin, Cholesterol. 
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Spectra No:5 FTIR of Doxorubicin Hcl, Soy lecithin, Cholesterol, Stearyl amine. 
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Spectra No:6 FTIR of Doxorubicin Hcl, Soy lecithin, Cholesterol, Dicetyl 
phosphate. 
Table No: 4 Interpretations of FTIR Spectra for pure drug. 
 
 
S.No. 
 
FUNCTIONAL GROUPS 
ASSESMENT PEAK 
OF PURE DRUG CM
-
1
 
RANGE OF 
GROUPS 
CM
-1
 
1. C=C Streching (Aromatic) 1463.86 
1524.51 
1450 – 1600 
2. O-H Bending (Alcohol) 1072.51 1050 - 1150 
3. C=O Streching 1729.84 1705 - 1735 
4. N-H Bending 1617.83 1500 – 1650 
5. C-O Streching (6-
Membered cyclic) 
1114.46 
1100 - 1120 
 
 
Table No: 5 Interpretations of FTIR Spectra for pure drug and Spectra-5 
 
 
S.No. 
 
FUNCTIONAL GROUPS 
ASSESMENT 
PEAK OF PURE 
DRUG CM
-1
 
ASSESMENT 
PEAK OF 
SPECTRA-5 
CM
-1
 
1. C=C Streching(Aromatic) 1463.86 
1524.51 
1466.09 
1524.38 
2. O-H Bending (Alcohol) 1072.51 1071.62 
3. C=O Streching 1729.84 1729.80 
4. N-H Bending 1617.83 1617.67 
5. C-O Streching (6-membered 
cyclic) 
1114.46 
1113.83 
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Table No: 6 Interpretations of FTIR Spectra for pure drug and Spectra-5 
 
 
S.No. 
 
FUNCTIONAL GROUPS 
ASSESMENT 
PEAK OF PURE 
DRUG CM
-1
 
ASSESMENT 
PEAK OF 
SPECTRA-1 CM
-
1
 
1. C=C Streching (Aromatic) 1463.86 
1524.51 
1466.26 
1524.48 
2. O-H Bending (Alcohol) 1072.51 1071.69 
3. C=O Streching 1729.84 1729.93 
4. N-H Bending 1617.83 1617.80 
5. C-O Streching (6-Membered 
cyclic) 
1114.46 
1113.89 
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Table No: 7 The composition and ratios of Soy lecithin, Cholesterol, 
Stearylamine, Dicetylphosphate and Ammonium Sulphate for different types of 
liposomes. 
 
Ratio of ingredients Tipes of liposomes 
Neutral Positive Negative 
Lecithin : cholesterol : 
Stearyl amine : 
Diacetylphosphate : 
Ammonium Sulphate  
5:5:0:0:30  5:5:1:0:30  5:5:0:1:30  
5.5:4.5:0:0:30  5.5:4.5:1:0:30  5.5:4.5:0:1:30  
6:4:0:0:30  6:4:1:0:30  6:4:0:1:30  
6.5:3.5:0:0:30  6.5:3.5:1:0:30  6.5:3.5:0:1:30  
7:3:0:0:30  7:3:1:0:30  7:3:0:1:30  
7.5:2.5:0:0:30  7.5:2.5:1:0:30  7.5:2.5:0:1:30  
8:2:0:0:30  8:2:1:0:30  8:2:0:1:30  
4.5:5.5:0:0:30  4.5:5.5:1:0:30  4.5:5.5:0:1:30  
4:6:0:0:30  4:6:1:0:30  4:6:0:1:30  
3:7:0:0:30  3:7:1:0:30  3:7:0:1:30  
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Table No: 8 The composition and ratios of Drug, Soy lecithin, Cholesterol, 
Stearylamine, Dicetylphosphate and Ammonium sulphate for optimized batches. 
 
Formul
ation 
code 
Drug 
(mg/ml) 
Soy 
lecithin 
(mg/ml) 
Cholesterol 
(mg/ml) 
Stearylamine 
(mg/ml) 
Dicetyl 
phosphate 
(mg/ml) 
Ammonim 
Sulphate 
(mg/ml) 
F1 2 7 3 - - 30 
F2 2 7.5 2.5 - - 30 
F3 2 7 3 1 - 30 
F4 2 7.5 2.5 1 - 30 
F5 2 7 3 - 1 30 
F6 2 7.5 2.5 - 1 30 
 
 
Table No: 9 Physicochemical characteristics of doxorubicin hydrochloride 
Liposomes for Optimized Batches. 
 
 
 
 
 
S.No. Formulation 
code 
Average vesicular      
size (nm) 
Zeta Potential 
(mV) 
Poly dispersive 
index (Pdi) 
1. F2 356nm 5.21 0.635 
 
2. F4 564nm 24.66 0.762 
 
3. F6 317nm -23.4 0.645 
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Report No: 1 Particle size distribution by wet method of Doxorubicin Hcl 
liposomal solution for F2 formulation. 
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Report No:2 Particle size distribution by wet method of Doxorubicin Hcl 
liposomal solution for F4 formulation. 
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Report No: 3 Particle size distribution by wet method of Doxorubicin Hcl 
liposomal solution for F6 formulation. 
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Report No: 4 Zeta potential for Doxorubicin Hcl Liposomal solution for F2 
formulation. 
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Report No: 5 Zeta potential for Doxorubicin Hcl Liposomal solution for F4 
formulation. 
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Report No: 6 Zeta potential for Doxorubicin Hcl Liposomal solution for F6 
formulation. 
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SCANNING ELECTRRON MICROSCOPY 
 
 
 
 
 
Fig No: 7 SEM photography of Liposomal solution for F2 formulation. 
 
 
 
 
 
 
 
Fig No: 8    SEM photography of Liposomal solution for F6 formulation. 
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Table No: 10 Percent free drug of Doxorubicin liposomal solution for F1, F2, F3, 
F4, F5 and F6 Formulations. (n=3) 
 
S. No. Formulation code Percentage of  free drug 
 
1. F1 13.36±1.1% 
2. F2 12.36±1.1% 
3. F3 12.56±4.6% 
4. F4 11.36±1.3% 
5. F5 8.45±5.9% 
6. F6 6.83±0.8% 
 
 
 
Table No: 11 Assay of Doxorubicin liposomal solution for F1, F2, F3, F4, F5, F6 
Formulations. (n=3) 
 
S. No. Formulation code Doxorubicin Hcl     
Assay 
1. F1 98.8±0.32% 
2. F2 99.7±0.65% 
3. F3 95.6±0.65% 
4. F4 97.3±0.96% 
5. F5 97.2±0.58% 
6. F6 98±1.32% 
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Graph N0:2 Percent free drug plot  for F1, F2 F3, F4, F5, F6 Formulations             
                                                          
 
 
 
 
Graph N0:3 Assay  plot  for F1, F2 F3, F4, F5, F6  Formulations 
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Table No: 12 In vitro cumulative % drug release profile of doxorubicin 
hydrochloride liposomal formulations. 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time (hrs) Cumulative % drug release 
F1 F2 F3 F4 F5 F6 
1 1.29 1.38 1.65 1.74 2.12 2.15 
2 2.36 2.92 3.21 3.37 4.02 4.07 
3 4.32 4.41 5.01 5.11 6.12 6.19 
4 5.65 5.93 6.56 6.82 8.32 8.43 
6 8.53 8.77 9.85 10.5 12.92 13.01 
8 11.21 11.65 13.56 13.9 17.53 17.62 
10 15.25 15.63 17.04 17.38 21.45 21.62 
12 18.65 18.91 20.53 20.86 25.35 25.56 
16 25.98 26.73 29.62 29.82 35.95 36.47 
20 33.85 34.25 36.56 36.78 44.86 45.07 
24 45.85 49.31 49.59 52.84 55.25 58.67 
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Graph N0:4 In vitro release study for F1 formulation. 
 
 
 
 
Graph No: 5 In vitro release study for F2 formulation. 
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Graph No: 6 In vitro release study for F3 formulation. 
 
 
 
 
Graph No: 7 In vitro release study for F4 formulation. 
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Graph No: 8 In vitro release study for F5 formulation. 
 
 
 
 
Graph No: 9 In vitro release study for F6 formulation. 
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Table No: 13 Zero order release model of doxorubicin hydrochloride liposomal 
Optimized formulations. 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
  
Time (hrs)                  Cumulative % drug release                
F2 F4 F6 
1 1.38 1.74 2.15 
2 2.92 3.37 4.07 
3 4.41 5.11 6.19 
4 5.93 6.82 8.43 
6 8.77 10.5 13.01 
8 11.65 13.9 17.62 
10 15.63 17.38 21.62 
12 18.91 20.86 25.56 
16 26.73 29.82 36.47 
20 34.25 36.78 45.07 
24 49.31 52.84 58.67 
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Table No: 14 First order release model of doxorubicin hydrochloride liposomal 
Optimized formulations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time (hrs) Log Remaining % drug release 
F2 F4 F6 
1 1.993 1.992 1.990 
2 1.987 1.985 1.981 
3 1.980 1.977 1.972 
4 1.973 1.969 1.961 
6 1.960 1.951 1.931 
8 1.946 1.935 1.915 
10 1.926 1.917 1.896 
12 1.908 1.898 1.871 
16 1.864 1.846 1.802 
20 1.817 1.800 1.739 
24 1.745 1.717 1.665 
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Table No: 15 Higuchi release model of doxorubicin hydrochloride liposomal 
Optimized formulations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  √t 
Cumulative % drug release 
F2              F4 F6 
1 1.38 1.74 2.15 
1.414 2.92 3.37 4.07 
1.732 4.14 5.11 6.19 
2 5.93 6.82 8.43 
2.449 8.77 10.5 13.01 
2.828 11.65 13.9 17.62 
3.162 15.63 17.38 21.26 
3.464 18.91 20.86 25.56 
4 26.73 29.82 36.47 
4.472 34.25 36.78 45.07 
4.898 49.31 52.84 58.67 
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Table No: 16 Korsmeyer-Peppas model for mechanism of drug release. 
 
 
Table No: 17 Curve fitting data of release rate profile of Formulatons F2, F4, F6. 
 
Type of 
Formulation 
Zero-order 
(R²) 
First-order 
(R²) 
Higuchi  
(R²) 
Korsmeyer – 
Peppas (n) 
F2 0.978 0.9758 0.9053 1.0890 
F4 0.9818 0.9761 0.9162 1.0483 
F6 0.9953 0.9869 0.9437 1.0502 
 
 
 
 
 
 
Log time 
Log  Cumulative % drug release 
F2 F4 F6 
0 0.139 0.240 0.332 
0.301 0.465 0.527 0.609 
0.477 0.644 0.708 0.719 
0.602 0.773 0.833 0.925 
0.778 0.942 1.021 1.114 
0.903 1.066 1.143 1.246 
1 1.193 1.240 1.334 
1.079 1.276 1.319 1.407 
1.204 1.426 1.474 1.561 
1.301 1.534 1.565 1.653 
1.380 1.692 1.722 1.768 
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Graph no: 10 Comparison of in vitro release studies for optimized formulations 
F2, F4, F6. 
 
 
 
Graph No: 11 Comparison of Zero order release studies for optimized 
formulations F2, F4, F6. 
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Graph No: 12 Comparison of First order release studies for optimized 
formulations F2, F4, F6. 
 
 
 
Graph No: 13 Comparison of Higuchi’s order plot for optimized formulations 
F2, F4, F6. 
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Graph No: 14 Comparison of Korsmeyer –Peppa’s model for optimized 
formulations F2, F4, F6. 
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Table No: 18 Effect of temperature on Assay of doxorubicin HCl at 4
o
c. 
 
Formulation 
code 
Effect of stability on Assay at 4
o
c 
0day 15 days 30 days 40 days 60 days 
F2 99.7±0.65% 99.2±0.47% 98.8±0.72% 98±1.0% 97.6±0.65% 
F4 97.3±0.96% 97.1±0.73% 96.6±1.12% 95.8±0.43% 95.2±0.96% 
F6 98±1.3% 97.5±1.0% 96.7±0.9% 96.2±0.63% 95.7±1.3% 
 
 
Table No: 19 Effect of temperature on Assay of doxorubicin HCl at room 
temperature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Formulation 
code 
Effect of stability on Assay at room temperature. 
0day 15 days 30 days 40 days 60 days 
F2 99.7±0.65% 97.8±0.48 96.4±0.54 94.92±0.32 93.56±0.85 
F4 97.3±0.96% 96.2±0.92 94.8±0.62 92.58±0.58 89.35±0.53 
F6 98±1.3% 97.8±0.65 95.9±0.69 92.52±0.86 90.24±0.74 
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Graph N0:15 Stability   plot for F1, F2 F3, F4, F5, F6 Formulations at 4
0
c 
 
 
 
  
Graph N0:16 Stability   plot for F1, F2 F3, F4, F5, F6 Formulations at Room 
temperature. 
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8. DISCUSSION 
 
8.1 Standard calibration curve of Doxorubicin hydrochloride in UV 
spectrophotometer: 
 
 The UV absorbance’s of Doxorubicin hydrochloride standard solution in the 
range of 10-50 µg/ml of drug in buffer, pH 7.4 showed linearity at λ max 254nm. The 
linearity was plotted for absorbance against concentration with R2 value 0.9995 and 
with the slope equation y=0.0179x-0.003. The absorbance values and standard curve 
shown in Table No:1  and Graph No:1 
 
8.2 Compatibility studies:   
 
The compatibility between the drug and the selected lipid and other excipients 
was evaluated using FTIR peak matching method. There was no appearance or 
disappearance of peaks in the drug-lipid mixture, which confirmed the absence of any 
chemical interaction between the drug, lipid and other chemicals. The results shown 
in Table No: 4, 5 and 6 and Spectra No: 1, 2, 3, 4, 5 and 6. 
 
8.3 Doxorubicin liposomal formulation: 
 
The Liposomes were prepared by dried thin film hydration technique using 
rotary evaporator with drug and carrier (soybean lecithin). 
 
The formulation containing Doxorubicin were prepared with different 
stabilizers like Dicetylphosphate and Stearylamine and all other parameters like 
temperature, vacuum and RPM were kept constant. The composition and ratios of 
compounds showed in Table No: 7. among those compositions 6 Formulations are 
selected as optimized batches for further evaluation, 2 from each of neutral, positive 
and negative as showed in Table No: 8 
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8.4 Physicochemical characterization 
 
8.4.1 Particle size distribution: 
 
The particle size distribution was analyzed for F2, F4, F6 formulations of 
doxorubicin Liposomes by wet method. The particle size was optimum in F6 
Formulation, When compared to F2 and F4, The results were shown in Table No: 9 
and Report No: 1, 2 and 3.  
 
8.4.2 Scanning Electron Microscopy: 
 
The Morphology and surface appearance of Liposomes were examined by 
using SEM. The SEM photographs of F2 and F6 formulation showed that the particles 
have smooth surface. The SEM images were shown in Figure No: 6 and 7.                          
 
8.4.3 Zeta Potential analysis: 
 
The zeta potential report of liposomal solution for F2, F4, F6 formulations are 
5.21mV, 24.66mV, -23.4 which lies near to the arbitary value. The report shows good 
stability value for formulated liposomal solution, the results were shown in Table No: 
9 and Report No: 4, 5 and 6. 
 
8.5 IN VITRO CHARACTERIZATION 
 
8.5.1 Percent free drug: 
 
The percent free drug is determined for all the formulations F1to F6. The 
percent free drug was optimum in F6 formulation, which is within the limit (10%), the 
percent free drug was as shown in the Table No: 10 and Graph No: 2 
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8.5.2 Assay: 
 
The assay value is determined for all the formulations from F1to F6. The assay 
value is within the limit (90%) for all the formulations, the results were shown in the 
Table No: 11 and Graph No: 3 
 
8.5.3 In vitro Dissolution data: 
 
The in vitro dissolution profile of prepared formulations was determined by 
membrane diffusion method. The dissolution was carried out for a period of 24 hrs in 
7.4 pH phosphate buffer. 
 
The cumulative percent release of F1 to F6 formulations at various time 
intervals was calculated and tabulated in Table No: 12 The cumulative percent drug 
release in all formulations was plotted against time in Graph No: 4, 5, 6, 7, 8, and 9. 
The Maximum percent of drug release was found in F6 formulation which contains 
maximum drug entrapment. 
  
8.5.4 Release Kinetics: 
 
The release kinetics of F2, F4, F6 formulations were studied. All formulations 
follow Zero order release kinetics and follow case II transport when it applied to the 
Korsmeyer-Peppa’s Model for mechanism of drug release. F6 formulation has better 
kinetic results when compared to F2 and F4 formulations. The results are shown in 
Table N0: 13, 14, 15 and 16 and Graph No: 10, 11, 12, 13 and 14. 
 
8.6 Stability data: 
 
The stability of the Doxorubicin Liposomes was evaluated after storage at 4
0
c 
and room temperature for 60 days. The assays of the samples were determined as a 
function of the storage time. The Liposomes stored at 4
0
c were found to be stable for 
duration of 60 days. The results were showed in Table No: 18 and 19 and Graph No: 
15 and 16. 
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9. SUMMARY AND CONCLUSION 
 
The main objective of this work was designed to prepare and evaluate the 
Doxorubicin Hcl Liposomes. This formulation will target the site of action with effect 
of various stabilizers on drug entrapment efficiency, and to reduce the side effects by 
formulating non-pegylated Liposomes. This liposomal formulation was formulated 
using the soyabeanlicithin and cholesterol which has lesser toxicity. 
 
The Liposomes were prepared by dried thin film hydration technique using 
rotary evaporator with drug, carrier, ammoniumsulphate and stabilizers. The 
parameters like temperature, vacuum and RPM were maintained accordingly. After 
preparation, the Liposomes were stored in freezed condition, and given for further 
evaluation. 
 
The prepared Liposomes of F2, F4 and F6 formulations were evaluated for 
physical and chemical characteristics like average vesicle size, shape and zeta 
potential. The evaluated batches showed good physicochemical characteristics in F6 
formulation (Negative) when compared to the F2 (Neutral) and F4 (Positive) 
formulations. 
 
The prepared Liposomes of F1 to F6 were evaluated for % free drug and 
Assay, The % Free drug was optimum in F6 (Negative) formulation when compared 
to other formulations of F1, F2, F3, F4 and F5. The Assay was optimum in F2 
(Neutral) formulation when compared to other formulations of F1, F3, F4, F5 and F6.  
 
This developed liposomal drug delivery system was also evaluated for 
dissolution study by pH 7.4 phosphate buffer using membrane diffusion method. The 
release of drug from F6(Negative) formulation was found to be sustained to certain 
extent when compared to F1, F2, F3, F4 and F5 formulations. 
 
The release kinetics of F2, F4 and F6 Formulations were studied. All 
formulations follow Case II transport when it applied to the Korsmeyer – Peppa’s 
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model for mechanism of drug release. F6 (negative) formulation has better kinetic 
results when compared to F2 and F4 formulations. 
 
The stability of the Doxorubicin Hcl Liposomes was evaluated after stored at 
4
o
c and room temperature for 60 days. The assay of the samples was determined as a 
function of the storage at different time intervals. The Liposomes stored at 4
o
c were 
found to be stable for duration of three months. 
 
From the results of physical characterization, in-vitro evaluation, release 
kinetics and stability studies, it was found that charged Liposomes containing 
Doxorubicin might be used for the treatment of a Kaposi’s sarcoma when compared 
to the normal drug and neutral Liposomes. 
 
CONCLUSION: 
 
From the executed experimental results, it could be concluded that the 
stabilizers like Stearylamine and Dicetylphosphate along with Soy lecithin and 
cholesterol were suitable carrier for the preparation of Doxorubicin Liposomes. 
Though the preliminary data based on in-vitro dissolution profile, release kinetics and 
stability studies proved that the suitability of such formulations, Still a thorough 
experiment will be required based on the animal studies. There after we can find the 
actual mode of action of this kind of dosage form. Therefore, a future work will be 
carried out as follows, 
 
 Long term stability studies 
 Invitro Cytotoxicity studies 
 Invivo Pharmacological work on animals. 
 Invivo pharmacokinetic studies on animals. 
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